Compass Therapeutics, INC

Compass Therapeutics presented updated corporate information, including data from its COMPANION-002 clinical study for tovecimig, highlighting significant improvements in key endpoints.

Compass Therapeutics, Inc. announced the final voting results from its Annual Meeting of Stockholders held on June 10, 2026, including the election of directors and ratification of its independent auditor.

Compass Therapeutics reported Q1 2026 financial results, highlighting positive Phase 2/3 data for tovecimig in biliary tract cancer and updates on other pipeline candidates.

Compass Therapeutics announced positive Phase 2/3 data for tovecimig in combination with paclitaxel for biliary tract cancer, meeting key PFS endpoint and showing significant ORR.

Compass Therapeutics announced its 2025 financial results, highlighting significant pipeline progress including key clinical trial milestones and a strong cash position extending into 2028.

Compass Therapeutics provided a corporate update, highlighting pipeline progress, strong cash position, and key leadership appointments.

Compass Therapeutics reports increased R&D spending and a net loss for Q1 2026, but positive topline results for tovecimig in biliary tract cancer.

Compass Therapeutics reported increased net losses in Q3 2025 but bolstered its financial position with a $129.3 million capital raise, extending its cash runway into 2028.

Compass Therapeutics reported an increased net loss for Q2 2025, driven by higher R&D expenses, and announced a delay in the overall survival analysis for its lead tovecimig Phase 2/3 study.

Compass Therapeutics' tovecimig, in combination with paclitaxel, achieved a statistically significant improvement in overall response rate in second-line biliary tract cancer patients, and the first patient was dosed in a front-line investigator-sponsored trial.

Compass Therapeutics reported its Q3 2024 financial results and provided updates on its clinical development programs, including discontinuing a Phase 2 trial for CTX-009 and planning a new trial.

Compass Therapeutics reported a net loss of $13.1 million for the second quarter of 2024, while advancing its clinical programs and securing a key milestone payment.

Compass Therapeutics, Inc. announced positive Phase 2/3 trial results for tovecimig in biliary tract cancer, alongside pipeline advancements and new executive hires, while reporting increased net losses for 2025.

Compass Therapeutics files its 10-K report for FY 2024, detailing its financial position and progress in developing antibody-based therapeutics for oncology.

Compass Therapeutics has formalized new employment agreements with key executives and filed its annual 10-K report, outlining financial performance and strategic direction.

General Counsel Jonathan Anderman acquired 25,000 shares of Compass Therapeutics common stock in an open market purchase.

Jonathan Anderman, General Counsel of Compass Therapeutics, Inc., acquired 25,000 shares of common stock.

Neil Lerner, Chief Accounting Officer at Compass Therapeutics, Inc., acquired 15,000 shares of common stock on April 29, 2026.

Compass Therapeutics CEO Thomas J. Schuetz disposed of 36,687 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Compass Therapeutics CEO Thomas J. Schuetz reported the sale of 46,777 shares of common stock to cover tax withholding obligations related to RSU vesting.

Compass Therapeutics General Counsel Jonathan Anderman received 150,000 restricted stock units and 720,000 stock options.

Compass Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, with a record date of April 15, 2026.

Compass Therapeutics has filed a definitive proxy statement with the SEC.

Compass Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Compass Therapeutics announces the resignation of Vered Bisker-Leib as CEO and the appointment of Thomas Schuetz as the new CEO, effective May 28, 2024.

Compass Therapeutics has filed a definitive proxy statement with the SEC.

Compass Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Commander Aggregator, LP and related entities report their beneficial ownership in Compass Therapeutics, Inc. has fallen to 4.5% due to an increase in the issuer's outstanding shares.

OrbiMed Advisors and OrbiMed Capital GP V LLC reported a decrease in their beneficial ownership of Compass Therapeutics, Inc. common stock to 8.9% due to an increase in the number of outstanding shares.

OrbiMed Advisors and affiliated entities have significantly reduced their beneficial ownership in Compass Therapeutics, Inc. by selling over 7 million shares, though they retain an 11.0% stake.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2025, as disclosed in a Schedule 13G filing dated January 21, 2026.

Vivo Opportunity Fund Holdings and its affiliates have disclosed a 5.1% passive beneficial ownership stake in Compass Therapeutics, Inc.

Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in Compass Therapeutics, Inc., comprising common stock and exercisable warrants.

Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in Compass Therapeutics, Inc., comprising common stock and exercisable warrants.

A group of entities led by Mark N. Lampert, including Biotechnology Value Fund L.P., has reported a collective beneficial ownership of 5.1% in Compass Therapeutics, Inc.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen have collectively reported significant beneficial ownership in Compass Therapeutics, Inc., with Suvretta and Cowen each holding 8.2% and Averill holding 7.1% of common stock.